

# P-aminosalicylate sodium



Essential medicine status

Section: [6. Anti-infective medicines](#) > [6.2. Antibacterials](#) > [6.2.5. Antituberculosis medicines](#)

EMLc

ATC codes: [J04AA01](#)

ICD11 code: [ML32.00](#)

Indication	Multi-drug resistant Mycobacterium tuberculosis
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.
Formulations	Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
EML status history	First added in 2023 ( <a href="#">TRS 1049</a> ) Changed in 2025 ( <a href="#">TRS 1064</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">P-aminosalicylate sodium</a>
DrugBank	<a href="#">P-aminosalicylate sodium (Aminosalicylic Acid)</a>

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.

